Compare TSLX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | VERA |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2011 | 2021 |
| Metric | TSLX | VERA |
|---|---|---|
| Price | $17.14 | $28.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $19.77 | ★ $74.20 |
| AVG Volume (30 Days) | 478.0K | ★ 1.6M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 10.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.82 | $863.11 |
| P/E Ratio | $116.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $23.05 |
| 52 Week High | $23.19 | $56.05 |
| Indicator | TSLX | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 42.13 |
| Support Level | $16.39 | $26.38 |
| Resistance Level | $17.94 | $36.95 |
| Average True Range (ATR) | 0.40 | 1.66 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 41.85 | 35.68 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.